Arginase promotes skeletal muscle arteriolar endothelial dysfunction in diabetic rats

Frontiers in Immunology

Volumn 4, Issue MAY, 2013, Pages

  Johnson, Fruzsina K ^a   Johnson, Robert A ^a   Peyton, Kelly J ^b   Shebib, Ahmad R ^b   Durante, William ^b  

^a LINCOLN MEMORIAL UNIVERSITY   (United States)

^b University of Missouri   (United States)

Author keywords

Arginase; Arginine; Diabetes; Endothelial dysfunction; Flow mediated vasodilation

Indexed keywords

ARGINASE; ARGINASE 1; ARGINASE 2; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; GRACILIS MUSCLE ARTERIOLE; HEART RATE; HEMODYNAMICS; MALE; MYOPATHY; NONHUMAN; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE ARTERIOLE; VASODILATATION;

EID: 84883781263     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00119     Document Type: Article

References (52)

1. Akbarzadeh, A., Norouzian, D., Mehrabi, M. R., Jamshidi, S., Farhangi, A., Allah Verdi, A., et al. (2007). Induction of diabetes by streptozotocin in rats. Indian J. Clin. Biochem. 22, 60-64.
2. Beckman, J. A., Creager, M. A., and Libby, P. (2002). Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 286, 2570-2581.
3. Beleznai, T., Feher, A., Spielvogel, D., Lansman, S. L., and Bagi, Z. (2011). Arginase I contributes to diminished coronary arteriolar dilation in patients with diabetes. Am. J. Physiol. Heart Circ. Physiol. 300, H777-H783.
4. Bolz, S. S., de Wit, C., and Pohl, U. (1999). Endothelium-derived hyperpolarizing factor but not NO reduces smooth muscle Ca2+ during acetylcholine-induced dilation of microvessels. Br. J. Pharmacol. 128, 124-134.
5. Christianson, D. W. (2005). Arginase: structure, mechanism, and physiological role in male and female sexual arousal. Acc. Chem. Res. 38, 191-201.
6. Demougeot, C., Prigent-Tesssier, A., Marie, C., and Berthelot, A. (2005). Arginase inhibition reduced endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J. Hypertens. 23, 971-978.
7. Dizikes, G. J., Grody, W. W., Kern, R. M., and Cederbaum, S. D. (1986). Isolation of human liver arginase cDNA and demonstration of nonhomology between the two human arginase genes. Biochem. Biophys. Res. Commun. 141, 53-59.
8. Duby, J. J., Campbell, R. K., Setter, S. M., White, J. R., and Rasmussen, K. A. (2004). Diabetic neuropathy: an intensive review. Am. J. Health Syst. Pharm. 61, 160-173.
9. Durante, W., Johnson, F. K., and Johnson, R. A. (2007). Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin. Exp. Pharmacol. Physiol. 34, 906-911.
10. Durante, W., Johnson, F. K., Johnson, R. A., Liu, X. M., Ensenat, D., and Peyton, K. J. (2006). Hyperglycemia stimulates vascular arginase activity. FASEB J. 20, A727, abstr. 465.5.
11. Durante, W., Sen, A. K., and Sunahara, F. A. (1988). Impairment of endothelial-dependent relaxation in aortae from spontaneously diabetic rats. Br. J. Pharmacol. 94, 463-468.
12. El-Bassossy, H. M., El-Fawal, R., and Fahmy, A. (2012). Arginase inhibition alleviates hypertension associated with diabetes: effect on endothelial dependent relaxation and NO production. Vascul. Pharmacol. 57, 194-200.
13. Elms, S. C., Toque, H. A., Rojas, M., Xu, Z., Caldwell, R. B., and Caldwell, R. W. (2013). The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia 56, 654-662.
14. Forstermann, U., and Sessa, W.C. (2012). Nitric oxide synthases: regulation and function. Eur. Heart J. 33, 829-837.
15. Goldberg, R. B. (2003). Cardiovascular disease in patients who have diabetes. Cardiol. Clin. 21, 399-413.
16. Gronros, J., Jung, C., Lundberg, J. O., Cerrato, R., Ostenson, C. G., and Pernow, J. (2011). Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 300, H1174-H1181.
17. Hattori, Y., Kawasaki, H., Abe, K., and Kanno, M. (1991). Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am. J. Physiol. 261, H1086-H1094.
18. Hoybergs, Y. M. J. J., Bierman, R. L. V., and Meert, T. F. (2008). The impact of body weight and body condition on behavioral testing for painful diabetic neuropathy in the streptozotocin rat model. Neurosci. Lett. 436, 13-18.
19. Johnson, F. K., Johnson, R. A., Peyton, K. J., and Durante, W. (2005). Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R1057-1062.
20. Johnson, F. K., and Johnson, R. A. (2008). Heme oxygenase-derived endogenous carbon monoxide impairs flow-induced dilation in resistance vessels. Shock 29, 526-530.
21. Johnson, M. T., Creager, S. J., Scales, K. M., Cusco, J. A., Lee, B. K., and Creager, M. A. (1993). Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88, 2510-2516.
22. Johnson, R. A., Durante, W., Craig, T., Peyton, K. J., Myers, J. G., Stewart, R. M., et al. (2010). Vascular arginase contributes to arteriolar endothelial dysfunction in a rat model of hemorrhagic shock. J. Trauma 69, 384-391.
23. Kannel, W. B., and McGee, D. L. (1979). Diabetes and cardiovascular disease: the Framingham study. JAMA 241, 2035-2038.
24. Kashyap, S. R., Lara, A., Zhang, R., Park, Y. M., and Defronzo, R. A. (2008). Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care 31, 134-139.
25. Kikkawa, R., Koya, D., and Haneda, M. (2003). Progression of diabetic nephropathy. Am. J. Kidney Dis. 41, S19-S21.
26. Kim, J. H., Bugai, L. J., Oh, Y. J., Bivalacqua, T. J., Ryoo, S., Soucy, K. G., et al. (2009). Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J. Appl. Physiol. 107, 1249-1257.
27. Kohli, R., Meininger, C. J., Haynes, T. E., Yan, W., Self, J. T., and Wu, G. (2004). Dietary L-arginine supplementation enhances endothelial nitric oxide synthesis in streptozotocin-induced diabetic rats. J. Nutr. 134, 600-608.
28. Lin, K. Y., Ito, A., Asagami, T., Tsao, P. S., Adimoolam, S., Kimoto, M., et al. (2002). Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106, 987-992.
29. Loscalzo, J., and Welch, G. (1995). Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis. 38, 87-104.
30. Ming, X.-F., Barandier, C., Viswambharan, H., Kwak, B. R., Mach, F., Mazzolai, L., et al. (2004). Thrombin stimulates human endothelial arginase enzymatic activity via the RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110, 3708-3714.
31. Ming, X.-F., Rajapakse, A. G., Yepuri, G., Xiong, Y., Carvas, J. M., Ruffieux, J., et al. (2012). Arginase II promotes macrophage inflammatory responses through mitochondrial reactive oxygen species, contributing to insulin resistance and atherogenesis. J. Am. Heart Assoc. 1, e000992.
32. Morris, S. M. Jr. (2009). Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol. 157, 922-930.
33. Morris, S. M. Jr., Gao, T., Cooper, T. K., Kepka-Lenhart, D., and Awad, A. S. (2011). Arginase-2 mediates diabetic renal injury. Diabetes 60, 3015-3022.
34. Nitenberg, A., Valensi, P., Sachs, R., Dali, M., Aptecar, E., and Attali, J. (1993). Impairment of coronary vascular reserve and acetylcholine-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42, 1017-1025.
35. Peyton, K. J., Ensenat, D., Azam, M. A., Keswani, A. N., Kannan, S., Liu, X.-M., et al. (2009). Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler. Thromb. Vasc. Biol. 29, 488-494.
36. Pieper, G. M., and Dondlinger, L. A. (1997). Plasma and vascular tissue arginine are decreased by diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J. Pharmacol. Exp. Ther. 283, 684-691.
37. Pieper, G. M., Siebeneich, W., Moore-Hilton, G., and Roza, A. M. (1997). Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia 40, 910-915.
38. Porta, M., and Bandello, F. (2002). Diabetic retinopathy: a clinical update. Diabetologia 45, 1617-1634.
39. Romero, M. J., Iddings, J. A., Platt, D. H., Ali, M. I., Cederbaum, S. D., Stepp, D. W., et al. (2012). Diabetes-induced vascular dysfunction involves arginase I. Am. J. Physiol. Heart Circ. Physiol. 302, H159-H166.
40. Romero, M. J., Platt, D. H., Tawfik, H. E., Labazi, M., El-Remessy, A. B., Bartoli, M., et al. (2008). Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ. Res. 102, 95-102.
41. Ryoo, S., Gupta, G., Benjo, A., Lim, H. K., Camara, A., Sikka, G., et al. (2008). Endothelial arginase II. A novel target for the treatment of atherosclerosis. Circ. Res. 102, 923-932.
42. Sasatomi, K., Hiragata, S., Miyazato, M., Chancellor, M. B., Morris, S. M. Jr., and Yoshimura, N. (2008). Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury. Urology 72, 696-700.
43. Shemyakin, A., Kovamees, O., Rafnsson, A., Bohm, F., Svenarud, P., Settergren, M., et al. (2012). Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes. Circulation 126, 2943-2950.
44. Sun, C., Sun, L., Ma, H., Peng, J., Zhen, Y., Duan, K., et al. (2012). The phenotype and functional alterations of macrophages in mice with hyperglycemia for long term. J. Cell. Physiol. 227, 1670-1679.
45. Tesfamariam, B., and Cohen, R. A. (1992). Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am. J. Physiol. 263, H321-H326.
46. Toque, H. A., Tostes, R. C., Yao, L., Xu, Z., Webb, R. C., Caldwell, R. B., et al. (2011). Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. J. Sex. Med. 8, 722-733.
47. Tribe, R. M., Thomas, C. R., and Poston, L. (1998). Flow-induced dilation in isolated resistance arteries from control and streptozotocin-diabetic rats. Diabetologia 41, 34-39.
48. Vockley, J. G., Jenkinson, C. P., Shukla, H., Kern, R. M., Grody, W. W., and Cederbaum, S. D. (1996). Cloning and characterization of the human type II arginase gene. Genomics 2, 118-123.
49. Wei, M., Ong, L., Smith, M. T., Ross, F. B., Schmid, K., Hoey, A. J., et al. (2003). The streptozotocin-diabetic rat model as a model of the chronic complications of human diabetes. Heart Lung Circ. 12, 44-50.
50. Winer, N., and Sowers, J. R. (2004). Epidemiology of diabetes. J. Clin. Pharmacol. 44, 397-405.
51. Wu, G., and Morris, S. M. Jr. (1998). Arginine metabolism: nitric oxide and beyond. Biochem. J. 336, 1-7.
52. Xu, W., Kaneko, F. T., Zheng, S., Comhair, S. A., Janocha, A. J., Goggans, T., et al. (2004). Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary hypertension. FASEB J. 18, 1746-1748.